Could Salts Be the Answer to Combatting Alzheimer's?

<u>Glen Hebberd</u>, Lee Higham*

School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle Upon Tyne, NE1 7RU

Introduction

Alzheimer's and Parkinson's Disease are widely known health issues that affect over 50 million people worldwide.^{1,2}

From previous research, we know that both diseases cause damage to a cell's mitochondria.³ The mitochondria produce the cell's energy, making itself negatively charged. If this part of the cell is damaged, then the negative charge is minimized or lost.

This means that a salt (a compound with positively and negatively charged components) can be manipulated to have a visible compound attached to the positive ion.

Theory

A **BODIPY** (BOron-DIPYrromethene) **core** is known to have fluorescent properties⁴, this means the compound absorbs radiation that we cannot see (such as UV light) and re-emits it at a longer wavelength which may be visible, or noticeable for medical imaging.

Due to the compound being a halogen salt (containing a fluoride, chloride, <u>bromide</u> or iodide ion) there is a good method to exchange the bromide, in this case, for a radioactive ¹⁹F ion. This can then be used as a radiolabel in Positron Emission Tomography (PET) scans, for which scanners are available in most larger hospitals.



Newcastle

University

If there is damage to the mitochondria, the positive ion will not congregate as normal and this will be visible to medical imaging techniques. Therefore, this compound has potential as an early detection method for these devastating diseases.

The alkyne group (C \equiv C) is within the molecule to allow it to be used in 'click chemistry' to easily attach a biomolecule at this position. This will allow a better uptake in the body, enabling the compound to enter the bloodstream and reach its targeted organelles (the mitochondria).

Figure 1: The final product (phosphonium) salt of BODIPY), labelled with colour for clarity.

Synthesis



Figure 2: The dichromatic (two-coloured) nature of the dyes synthesised.





Figure 3: A typical column chromatography, used for purification of each compound.

Acknowledgements

Analysis

NMR (Nuclear Magnetic Resonance) is a vital analytical technique used in chemistry. It can help identify and characterise many different classes of compounds. It is also able to give some assessment of purity and to identify changes to a compound's structure or composition.

Shown (*right*) are some spectra obtained from compounds **1**, **2b** & **3** above with the key differences highlighted. The data points from these were also cross-referenced to previously reported data^{5,6,7} to ensure the desired compounds were correctly synthesised.



Figure 4: Three ¹H NMR spectra for three different compounds, as labelled. The differences in the spectra are emphasised and demonstrated in the *Synthesis* section above.

I would like to thank Newcastle University and Dr Lee Higham for their funding. I would also like to thank the LJH Research group for their support, expertise and use of equipment.

References

Alzheimer's Disease Statistics, https:// alzheimersnewstoday.com/alzheimers-disease-statistics (accessed: September 2019).

² Parkinson's Foundation, https://www.parkinson.org/ Understanding-Parkinsons/Statistics (accessed: September 2019).

³ S. C. Correia, in *Neurodegenerative Diseases*, ed. S. I. Ahmad, Springer-Verlag, New York, 2012, vol. 724, pp. 205-221. G. Ulrich, R. Ziessel, A. Harriman, Angew Chem Int Ed, 2008, 47, 1184-1201.

⁵ J. F. Wallis, PhD Thesis, Newcastle University, 2017.

- ⁶ L. H. Davies, J. F Wallis *et al., Synthesis*, 2014, **46**, 2622-2628.
- L. H. Davies, B. Stewart *et al., Angew Chem Int Ed,* 2012, **51**,
- 4921-4924.

🕻: (i) TFA, (ii) DDQ, (iii) DIPEA, (iv) Et₂O,BF2, (v) DCM, (vi) MeLi, (vii) Anhvd, THF, (viii) [Pd(PPh2)4], (ix) Diethylphosphite, (x) DMS(